Hip fractures attributable to corticosteroid use

Lancet

Volumn 353, Issue 9161, 1999, Pages 1327-

  Baltzan, Marc A ^a,b   Suissa, Samy ^a,b   Bauer, Douglas C ^a,b   Cummings, Steven R ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; CORTICOSTEROID;

AGED; ARTICLE; BONE DENSITY; BONE MINERAL; FEMALE; HIP FRACTURE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0033577448     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04835-1     Document Type: Article

References (5)

1. Elfforts I, Allander E, Kanis JA, et al. The variable incidence of hip fracture in Southern Europe: MEDOS study. Osteoporosis Int 1994; 4:253-63.
2. Saito JK, Davis JW, Wasnich RD, Ross PD. Users of low-dose corticosteroids have increased bone loss rates: a longitudinal study. Calcij Tissue Int 1995; 57: 1 15-19.
3. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309:265-68.
4. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767-73.
5. Cooper C, Coupland M, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54: 49-52.